Dyadic International Secures Grant from Bill & Melinda Gates Foundation

On November 16, 2024, Dyadic International, Inc. announced the execution of a significant agreement with the Bill & Melinda Gates Foundation. The company has received a grant totaling $3,092,136.00 from the Gates Foundation. This grant is specifically designated to fund the cell line development of monoclonal antibodies geared towards combating respiratory syncytial virus and malaria. Dyadic International plans to leverage its proprietary C1 protein production platform to create accessible treatment solutions for underserved populations globally.

Following this development, Dyadic International, Inc. released a press statement on November 21, 2024, detailing the specifics of the Gates Foundation Grant. The company furnished the press release as Exhibit 99.1 in its Current Report on Form 8-K. The press release outlines the objectives and implications of the grant, with the exception of the third paragraph.

In accordance with the disclosure requirements, Dyadic International, Inc. provided the relevant financial statements and exhibits concerning this transaction. The company filed Exhibit 10.1, the Grant Agreement between Dyadic International and the Gates Foundation dated November 16, 2024, and Exhibit 99.1, the Dyadic International Press Release dated November 21, 2024. Additionally, Exhibit 104, the Cover Page Interactive Data File, was included in the submission.

Portions of the grant agreement exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Dyadic International, Inc. confirmed the authenticity of the report with the undersigned Mark A. Emalfarb, Chief Executive Officer, signing off on behalf of the company on November 26, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Dyadic International’s 8K filing here.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.